Atrium Therapeutics, Inc. (RNA)
NasdaqGS · USD · Healthcare · Biotechnology
$8.26 (+2.55%) as of
Key statistics
- Market cap
- 141.21M
- Forward P/E
- -1.39
- EPS (TTM)
- -5.44
- Dividend yield
- 0.00%
- 52-week range
- 7.49 – 16.77
- Revenue (TTM)
- 35.84M
- Profit margin
- -184.15%
- Analyst target
- $23.00
- Volume
- 46.41k
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.